|Trade names||Lamictal, others|
|Other names||BW-430C; BW430C; 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine|
|Oral (by mouth)|
|Metabolism||Liver (mostly UGT1A4-mediated)|
|Elimination half-life||29 hours|
|Excretion||Urine (65%), feces (2%)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||256.09 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Lamotrigine, sold under the brand name Lamictal among others, is a medication used to treat epilepsy and stabilize mood in bipolar disorder. For epilepsy, this includes focal seizures, tonic-clonic seizures, and seizures in Lennox-Gastaut syndrome. In bipolar disorder, lamotrigine has not been shown to reliably treat acute depression; but for patients with bipolar disorder who are not currently symptomatic, it appears to be effective in reducing the risk of future episodes of depression.
Common side effects include nausea, sleepiness, headache, vomiting, trouble with coordination, and rash. Serious side effects include excessive breakdown of red blood cells, increased risk of suicide, severe skin reaction (Stevens–Johnson syndrome), and allergic reactions, which can be fatal. Lamotrigine is a phenyltriazine, making it chemically different from other anticonvulsants. Its mechanism of action is not clear, but it appears to inhibit release of excitatory neurotransmitters via voltage-sensitive sodium channels and voltage-gated calcium channels in neurons.
Lamotrigine was first marketed in Ireland in 1991, and approved for use in the United States in 1994. It is on the World Health Organization's List of Essential Medicines. In 2020, it was the 62nd most commonly prescribed medication in the United States, with more than 10 million prescriptions.
Lamotrigine is considered a first-line drug for primary generalized tonic-clonic seizures (includes simple partial, complex partial, and secondarily generalized seizures such as focal-onset tonic-clonic seizures). It is also used as an alternative or adjuvant medication for partial seizures, such as absence seizure, myoclonic seizure, and atonic seizures. A 2020 review on the use of lamotrigine as an add-on therapy for drug resistant generalized tonic-clonic seizures was unable to come to conclusions to inform clinical practice. Although low-certainty evidence suggest that it reduces generalized tonic-clonic seizures by 50% the level of uncertainty indicates that the actual findings could be significantly different. Another 2020 Cochrane review examining the use of lamotrigine as an add-on therapy for drug-resistant focal epilepsy found it to be effective for reducing seizure frequency and was well tolerated.
Lamotrigine is one of a small number of FDA-approved therapies for the form of epilepsy known as Lennox–Gastaut syndrome. It reduces the frequency of LGS seizures, and is one of two medications known to decrease the severity of drop attacks. Combination with valproate is common, but this increases the risk of lamotrigine-induced severe skin reaction Stevens–Johnson syndrome, and necessitates reduced dosing due to the interaction of these drugs.
Lamotrigine is approved in the US for maintenance treatment of bipolar I disorder and bipolar II disorder. While the anticonvulsants carbamazepine and valproate are predominantly antimanics, lamotrigine has demonstrated efficacy only in preventing or reducing the risk of recurrent depressive episodes of bipolar disorder. The drug seems ineffective in the treatment of current rapid-cycling, acute mania, or acute depression in bipolar disorder. Lamotrigine has been shown to be as effective as lithium, the standard treatment for bipolar disorder.
Lamotrigine has not demonstrated clear efficacy in treating acute mood episodes, either mania or depression. It has not demonstrated effectiveness in treating acute mania, and there is controversy regarding the drug's effectiveness in treating acute bipolar depression. A paper written in 2008 by Nassir et al. reviewed evidence from trials that were unpublished and not referenced in the 2002 APA guidelines, and it concludes that lamotrigine has "very limited, if any, efficacy in the treatment of acute bipolar depression". A 2008 paper by Calabrese et al. examined much of the same data, and found that in five placebo-controlled studies, lamotrigine did not significantly differ from placebo in the treatment of bipolar depression. However, in a meta-analysis of these studies conducted in 2008, Geddes, Calabrese and Goodwin found that lamotrigine was effective in individuals with bipolar depression, with a number needed to treat (NNT) of 11, or 7 in severe depression.
A 2013 review concluded that lamotrigine is recommended in bipolar maintenance when depression is prominent and that more research is needed in regard to its role in the treatment of acute bipolar depression and unipolar depression. No information to recommend its use in other psychiatric disorders was found.
Lamotrigine, as a monotherapy, is not substantially effective against schizophrenia. However, various publications and textbooks have expressed that lamotrigine could be added to clozapine as augmentation therapy against partial or non-responding schizophrenic patients. Patients had statistically significant improvements in positive, negative and affective symptoms. Lamotrigine does not have a statistically significant effect with antipsychotics other than clozapine, such as: olanzapine, risperidone, haloperidol, zuclopenthixol, etc.
Off-label uses include the treatment of peripheral neuropathy, trigeminal neuralgia, cluster headaches, migraines, visual snow, and reducing neuropathic pain, although a systematic review conducted in 2013 concluded that well-designed clinical trials have shown no benefit for lamotrigine in neuropathic pain. Off-label psychiatric usage includes the treatment of treatment-resistant obsessive-compulsive disorder, depersonalization disorder, hallucinogen persisting perception disorder, schizoaffective disorder, and borderline personality disorder. It has not been shown to be useful in post-traumatic stress disorder.
GlaxoSmithKline investigated lamotrigine for the treatment of ADHD with inconclusive results. No detrimental effects on cognitive function were observed; however, the only statistical improvement in core ADHD symptoms was an improvement on a Paced Auditory Serial Addition Test that measures auditory processing speed and calculation ability. Another study reported that lamotrigine might be a safe and effective treatment option for adult ADHD comorbid with bipolar and recurrent depression.
Lamotrigine prescribing information has a black box warning about life-threatening skin reactions, including Stevens–Johnson syndrome (SJS), DRESS syndrome, and toxic epidermal necrolysis (TEN). The manufacturer states that nearly all cases appear in the first two to eight weeks of therapy. Patients should seek medical attention for any unexpected skin rash, as its presence is an indication of a possible serious or even deadly side effect of the drug. Not all rashes that occur while taking lamotrigine progress to SJS or TEN. Between 5 and 10% of patients will develop a rash, but only one in a thousand patients will develop a serious rash. Rash and other skin reactions are more common in children, so this medication is often reserved for adults. For patients whose lamotrigine has been stopped after development of a rash, rechallenge with lamotrigine is also a viable option. However, it is not applicable for very serious cases. The incidence of these eruptions increases in patients who are currently on, or recently discontinued a valproate-type anticonvulsant drug, as these medications interact in such a way that the clearance of both is decreased and the effective dose of lamotrigine is increased.
Other side effects include alopecia (hair loss), loss of balance or coordination, double vision, crossed eyes, pupil constriction, blurred vision, dizziness and lack of coordination, drowsiness, insomnia, anxiety, vivid dreams or nightmares, dry mouth, mouth ulcers, memory problems, mood changes, itchiness, runny nose, cough, nausea, indigestion, abdominal pain, weight loss, missed or painful menstrual periods, and vaginitis. The side-effects profile varies for different patient populations. Overall adverse effects in treatment are similar between men, women, geriatric, pediatric and racial groups.
A systematic review of the literature revealed that abnormal movements secondary to lamotrigine are uncommon. The movement disorders associated with lamotrigine were tics, akathisias, dyskinesias, myoclonus, parkinsonism, dystonia, cerebellar syndromes, and stuttering.
Women are more likely than men to have side effects.
Some evidence shows interactions between lamotrigine and female hormones, which can be of particular concern for women on estrogen-containing hormonal contraceptives. Ethinylestradiol, an ingredient of such contraceptives, has been shown to decrease serum levels of lamotrigine. Women starting an estrogen-containing oral contraceptive may need to increase the dosage of lamotrigine to maintain its level of efficacy. Likewise, women may experience an increase in lamotrigine side effects upon discontinuation of birth control pills. This may include the "pill-free" week where lamotrigine serum levels have been shown to increase twofold.
Pregnancy and breastfeeding
Many studies have found no association between lamotrigine exposure in utero and birth defects, while those that have found an association have found only slight associations with minor malformations such as cleft palates. Review studies have found that overall rates of congenital malformations in infants exposed to lamotrigine in utero are relatively low (1-4%), which is similar to the rate of malformations in the general population. It is known that lamotrigine is a weak inhibitor of human dihydrofolate reductase (DHFR) and other, more powerful, human DHFR inhibitors such as methotrexate are known to be teratogenic.
Lamotrigine is expressed in breast milk; the manufacturer recommends carefully weighing the benefits and risks of taking Lamotrigine while breastfeeding. However, some studies suggest that lamotrigine is safe to use while breastfeeding. A frequently updated review of scientific literature rates lamotrigine as L3: moderately safe.
Other types of effects
Lamotrigine is known to affect sleep. Studies with small numbers of patients (10–15) reported that lamotrigine increases the duration of REM sleep, decreases the number of phase shifts, and decreases the duration of slow-wave sleep, and that there was no effect on vigilance, daytime somnolence and cognitive function. However, a retrospective study of 109 patients' medical records found that 6.7% of patients experienced an "alerting effect" resulting in intolerable insomnia, for which the treatment had to be discontinued.
Lamotrigine can induce a type of seizure known as a myoclonic jerk, which tends to happen soon after the use of the medication. When used in the treatment of myoclonic epilepsies such as juvenile myoclonic epilepsy, lower doses (and lower plasma levels) are usually needed, as even moderate doses of this drug can induce seizures, including tonic-clonic seizures, which can develop into status epilepticus, which is a medical emergency. It can also cause myoclonic status epilepticus.
In overdose, lamotrigine can cause uncontrolled seizures in most people. Reported results in overdoses involving up to 15 g include increased seizures, coma, and death.
Mechanism of action
Lamotrigine is a member of the sodium channel blocking class of antiepileptic drugs. This may suppress the release of glutamate and aspartate, two dominant excitatory neurotransmitters in the central nervous system. It is generally accepted to be a member of the sodium channel blocking class of antiepileptic drugs, but it could have additional actions, since it has a broader spectrum of action than other sodium channel antiepileptic drugs such as phenytoin and is effective in the treatment of the depressed phase of bipolar disorder, whereas other sodium channel-blocking antiepileptic drugs are not, possibly on account of its sigma receptor activity. In addition, lamotrigine shares few side effects with other, unrelated anticonvulsants known to inhibit sodium channels, which further emphasizes its unique properties.
It is a triazine derivate that inhibits voltage-sensitive sodium channels, leading to stabilization of neuronal membranes. It also blocks L-, N-, and P-type calcium channels and weakly inhibits the serotonin 5-HT3 receptor. These actions are thought to inhibit release of glutamate at cortical projections in the ventral striatum limbic areas, and its neuroprotective and antiglutamatergic effects have been pointed out as promising contributors to its mood stabilizing activity. Observations that lamotrigine reduced γ-aminobutyric acid (GABA) A receptor-mediated neurotransmission in rat amygdala, suggest that a GABAergic mechanism may also be involved. It appears that lamotrigine does not increase GABA blood levels in humans.
Lamotrigine does not have pronounced effects on any of the usual neurotransmitter receptors that anticonvulsants affect (adrenergic, dopamine D1 and D2, muscarinic, GABA, histaminergic H1, serotonin 5-HT2, and N-methyl-D-aspartate). Inhibitory effects on 5-HT, norepinephrine, and dopamine transporters are weak. Lamotrigine is a weak inhibitor of dihydrofolate reductase, but whether this effect is sufficient to contribute to a mechanism of action or increases risk to the fetus during pregnancy is not known. Early studies of lamotrigine's mechanism of action examined its effects on the release of endogenous amino acids from rat cerebral cortex slices in vitro. As is the case for antiepileptic drugs that act on voltage-dependent sodium channels, lamotrigine thereby inhibits the release of glutamate and aspartate, which is evoked by the sodium-channel activator veratrine, and was less effective in the inhibition of acetylcholine or GABA release. At high concentrations, it had no effect on spontaneous or potassium-evoked amino acid release.
These studies suggested that lamotrigine acts presynaptically on voltage-gated sodium channels to decrease glutamate release. Several electrophysiological studies have investigated the effects of lamotrigine on voltage-gated sodium channels. For example, lamotrigine blocked sustained repetitive firing in cultured mouse spinal cord neurons in a concentration-dependent manner, at concentrations that are therapeutically relevant in the treatment of human seizures. In cultured hippocampal neurons, lamotrigine reduced sodium currents in a voltage-dependent manner, and at depolarised potentials showed a small frequency-dependent inhibition. These and a variety of other results indicate that the antiepileptic effect of lamotrigine, like those of phenytoin and carbamazepine, is at least in part due to use- and voltage-dependent modulation of fast voltage-dependent sodium currents. However, lamotrigine has a broader clinical spectrum of activity than phenytoin and carbamazepine and is recognised to be protective against generalised absence epilepsy and other generalised epilepsy syndromes, including primary generalised tonic–clonic seizures, juvenile myoclonic epilepsy, and Lennox-Gastaut syndrome.
The basis for this broader spectrum of activity of lamotrigine is unknown, but could relate to actions of the drug on voltage-gated calcium channels. Lamotrigine blocks T-type calcium channels weakly, if at all. However, it does inhibit native and recombinant high voltage–gated calcium channels (N- and P/Q/R-types) at therapeutic concentrations. Whether this activity on calcium channels accounts for lamotrigine's broader clinical spectrum of activity in comparison with phenytoin and carbamazepine remains to be determined.
It antagonises these receptors with the following IC50 values:
- 5-HT3, IC50 = 18 μM
- σ receptors, IC50 = 145 μM
The pharmacokinetics of lamotrigine follow first-order kinetics, with a half-life of 29 hours and volume of distribution of 1.36 L/kg. Lamotrigine is rapidly and completely absorbed after oral administration. Its absolute bioavailability is 98% and its plasma Cmax occurs from 1.4 to 4.8 hours. Available data indicate that its bioavailability is not affected by food. Estimate of the mean apparent volume of distribution of lamotrigine following oral administration ranges from 0.9 to 1.3 L/kg. This is independent of dose and is similar following single and multiple doses in both patients with epilepsy and in healthy volunteers.
Lamotrigine is inactivated by glucuronidation in the liver. Lamotrigine is metabolized predominantly by glucuronic acid conjugation. Its major metabolite is an inactive 2-n-glucuronide conjugate.
Lamotrigine has fewer drug interactions than many anticonvulsant drugs, although pharmacokinetic interactions with carbamazepine, phenytoin and other hepatic enzyme inducing medications may shorten half-life. Dose adjustments should be made on clinical response, but monitoring may be of benefit in assessing compliance.
The capacity of available tests to detect potentially adverse consequences of melanin binding is unknown. Clinical trials excluded subtle effects and optimal duration of treatment. There are no specific recommendations for periodic ophthalmological monitoring. Lamotrigine binds to the eye and melanin-containing tissues which can accumulate over time and may cause toxicity. Prescribers should be aware of the possibility of long-term ophthalmologic effects and base treatment on clinical response. Patient compliance should be periodically reassessed with lab and medical testing of liver and kidney function to monitor progress or side effects.
The first synthesis of lamotrigine was disclosed in a patent filed by the Wellcome Foundation in 1980. 2,3-Dichlorobenzoyl chloride is treated with cuprous cyanide to form an acyl cyanide. This is then reacted with the nitrate salt of aminoguanidine to give an intermediate which is cyclised to the diamino triazine of the drug product.
- 1980 — initial patent filings are made by the Wellcome Foundation.
- 1990 — lamotrigine is approved for use in Ireland to treat epilepsy.
- 1991 — lamotrigine is used in the United Kingdom as an anticonvulsant medication
- December 1994 — lamotrigine was approved for use in the United States for the treatment of partial seizures.
- August 1998 — for use as adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients, new dosage form: chewable dispersible tablets.
- December 1998 — for use as monotherapy for treatment of partial seizures in adult patients when converting from a single enzyme-inducing anticonvulsant drug.
- January 2003 — for use as adjunctive therapy for partial seizures in pediatric patients as young as two years of age.
- June 2003 — approved for maintenance treatment of bipolar II disorder; the first such medication since lithium.
- January 2004 — for use as monotherapy for treatment of partial seizures in adult patients when converting from the anti-epileptic drug valproate (including valproic acid)
Society and culture
Regulatory advisory in 2021
In March 2021, the United States Food and Drug Administration (FDA) issued a warning regarding the potential for cardiac arrhythmias in people with pre-existing structural or conduction heart defects. The warning provoked consternation and controversy within the professional community. An in-vitro study conducted in 2011 predicted Class IB antiarrhythmic activity at therapeutic concentrations of lamotrigine, due to its sodium channel-blocking activity. Thus, lamotrigine use in at-risk populations could prolong the QRS interval on the electrocardiogram, and increase the risk of arrhythmias and sudden death. No references to human studies or postmarket data in at-risk populations (i.e., people with structural heart disease) were cited to support the warning. A study in dogs is mentioned in the prescribing information brochure by the manufacturer. A rapid systematic review concluded that "there is insufficient evidence to support or refute that lamotrigine is associated with sudden death or electrocardiogram changes..." The FDA has recommended that further studies are conducted with lamotrigine and other sodium-channel blocking antiseizure medications.
In March 2023, a FAERS (FDA Adverse Event Reporting System) analysis demonstrated signals of cardiac arrest, but not of tachyarrhythmia or bradyarrhythmia nor their clinical manifestation as fainting in lamotrigine. The study stratified the epileptic and psychiatric indications, explaining that the nature of the signal for cardiac arrest seems to be confounded by the psychiatric indication, which included 2.5 times more concomitant medications with cardiac adverse events, such as QT-prolonging drugs. Additionally, a 1.5-fold greater reports on overdose and suicide attempts was recorded in the psychiatric reports. Although lamotrigine blocks the cardiac sodium channels at therapeutically relevant concentrations, owing to its short-fast kinetics at the channel level, this blockage did not translate into a disproportionality signal in this study.
Though lamotrigine has been used to treat seizures in infants, as of 2023, its effectiveness in this age group has been evaluated in only one study. Adverse effects were rarely severe enough for the medication to be discontinued in this age group, however, its effectiveness in reducing seizures was inconclusive.
- "Lamotrigine". Drugs.com. Archived from the original on 10 December 2017. Retrieved 9 December 2017.
- "Lamotrigine Use During Pregnancy". Drugs.com. 8 October 2019. Archived from the original on 25 January 2021. Retrieved 24 March 2020.
- Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
- "Lamictal- lamotrigine tablet Lamictal- lamotrigine tablet, for suspension Lamictal ODT- lamotrigine tablet, orally disintegrating Lamictal- lamotrigine kit". DailyMed. 13 April 2022. Archived from the original on 27 August 2022. Retrieved 27 August 2022.
- "Lamictal XR- lamotrigine tablet, film coated, extended release Lamictal XR- lamotrigine kit". DailyMed. 13 April 2022. Archived from the original on 27 August 2022. Retrieved 27 August 2022.
- "Lamictal". European Medicines Agency. 17 September 2018. Archived from the original on 27 August 2022. Retrieved 27 August 2022.
- "Lamotrigine". The American Society of Health-System Pharmacists. Archived from the original on 10 December 2017. Retrieved 8 December 2017.
- "Lamotrigine: Its Role in Bipolar Disorder". PsychiatricTimes. 26 November 2019. Archived from the original on 26 January 2021. Retrieved 1 September 2020.
- "Lamotrigine". PubChem Open Chemistry Database. US: National Institutes of Health. Archived from the original on 6 September 2016. Retrieved 13 December 2016.
- Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM (1 October 2003). "Lamotrigine: a review of its use in bipolar disorder". Drugs. 63 (19): 2029–2050. doi:10.2165/00003495-200363190-00009. PMID 12962521. Archived from the original on 27 August 2022. Retrieved 15 January 2022.
- Weisler RH, Calabrese JR, Bowden CL, Ascher JA, DeVeaugh-Geiss J, Evoniuk G (May 2008). "Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence". Journal of Affective Disorders. 108 (1–2): 1–9. doi:10.1016/j.jad.2007.09.012. PMID 18001843.
- Shorvon SD, Perucca E, Engel J (2015). The Treatment of Epilepsy (4th ed.). John Wiley & Sons, Incorporated. p. 1321. ISBN 9781118936993. Archived from the original on 2 August 2021. Retrieved 31 August 2020.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 7 October 2022.
- "Lamotrigine - Drug Usage Statistics". ClinCalc. Archived from the original on 28 February 2020. Retrieved 7 October 2022.
- Kasper D (2005). Kasper D, Braunwald E, Fauci A, Hauser S, Longo D, Jameson J, et al. (eds.). Harrison's Principles of Internal Medicine (16th ed.). McGraw-Hill. pp. 3–22. ISBN 9780071466332.
- Tierny LM (2006). McPhee SJ, Papadakis MA (eds.). Current Medical Diagnosis and Treatment, 45th ed. McGraw-Hill. ISBN 978-0071454100.
- Bresnahan R, Panebianco M, Marson AG (July 2020). "Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures". The Cochrane Database of Systematic Reviews. 2020 (7): CD007783. doi:10.1002/14651858.CD007783.pub3. PMC 7387132. PMID 32609387.
- Panebianco M, Bresnahan R, Ramaratnam S, Marson AG (March 2020). "Lamotrigine add-on therapy for drug-resistant focal epilepsy". The Cochrane Database of Systematic Reviews. 2020 (3): CD001909. doi:10.1002/14651858.CD001909.pub3. PMC 7083514. PMID 32196639.
- Brigo F, Jones K, Eltze C, Matricardi S (April 2021). "Anti-seizure medications for Lennox-Gastaut syndrome". The Cochrane Database of Systematic Reviews. 4 (4): CD003277. doi:10.1002/14651858.CD003277.pub4. PMC 8095011. PMID 33825230.
- French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. (April 2004). "Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society". Neurology. 62 (8): 1261–1273. doi:10.1212/01.WNL.0000123695.22623.32. PMID 15111660. Archived from the original on 16 December 2004. Retrieved 2 April 2005.
- Pellock JM (November 1999). "Managing pediatric epilepsy syndromes with new antiepileptic drugs". Pediatrics. 104 (5 Pt 1): 1106–1116. doi:10.1542/peds.104.5.1106. PMID 10545555. S2CID 1090325.
- GlaxoSmithKline (12 October 2010). "Lamictal (lamotrigine) Label Information" (PDF). Food and Drug Administration. Archived from the original (PDF) on 20 April 2017. Retrieved 5 August 2019.
- Nassir Ghaemi S, Shirzadi AA, Filkowski M (2008). "Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder". Medscape Journal of Medicine. 10 (9): 211. PMC 2580079. PMID 19008973.
- Hashimoto Y, Kotake K, Watanabe N, Fujiwara T, Sakamoto S (September 2021). "Lamotrigine in the maintenance treatment of bipolar disorder". The Cochrane Database of Systematic Reviews. 2021 (9): CD013575. doi:10.1002/14651858.CD013575.pub2. PMC 8440301. PMID 34523118.
- Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM (2003). "Lamotrigine: a review of its use in bipolar disorder". Drugs. 63 (19): 2029–2050. doi:10.2165/00003495-200363190-00009. PMID 12962521.
- Geddes JR, Miklowitz DJ (May 2013). "Treatment of bipolar disorder". Lancet. 381 (9878): 1672–1682. doi:10.1016/S0140-6736(13)60857-0. PMC 3876031. PMID 23663953.
- Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, et al. (March 2008). "Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials". Bipolar Disorders. 10 (2): 323–333. doi:10.1111/j.1399-5618.2007.00500.x. PMID 18271912.
- Geddes JR, Calabrese JR, Goodwin GM (January 2009). "Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials". The British Journal of Psychiatry. 194 (1): 4–9. doi:10.1192/bjp.bp.107.048504. PMID 19118318.
- Reid JG, Gitlin MJ, Altshuler LL (July 2013). "Lamotrigine in psychiatric disorders". The Journal of Clinical Psychiatry. 74 (7): 675–684. doi:10.4088/JCP.12r08046. PMID 23945444.
- Tiihonen J, Wahlbeck K, Kiviniemi V (April 2009). "The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis". Schizophrenia Research. 109 (1–3): 10–14. doi:10.1016/j.schres.2009.01.002. PMID 19186030. S2CID 25302931.
- Dursun SM, McIntosh D, Milliken H (October 1999). "Clozapine plus lamotrigine in treatment-resistant schizophrenia". Archives of General Psychiatry. 56 (10): 950. doi:10.1001/archpsyc.56.10.950. PMID 10530638.
- Taylor DM (2018). The Maudsley Prescribing Guidelines in Psychiatry. Hoboken, NJ: Wiley. p. 159. ISBN 9781119442561.
- Stahl SM (2017). Stahl's Essential Psychopharmacology Prescriber's Guide (6th ed.). Cambridge: Cambridge University Press. p. 178. ISBN 9781316618134.
- Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, Heresco-Levy U (September 2004). "Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia". Biological Psychiatry. 56 (6): 441–446. doi:10.1016/j.biopsych.2004.06.029. PMID 15364042. S2CID 7479755.
- Backonja M (June 2004). "Neuromodulating drugs for the symptomatic treatment of neuropathic pain". Current Pain and Headache Reports. 8 (3): 212–216. doi:10.1007/s11916-004-0054-4. PMID 15115640. S2CID 24786792.
- Jensen TS (2002). "Anticonvulsants in neuropathic pain: rationale and clinical evidence". European Journal of Pain. 6 Suppl A (Suppl A): 61–68. doi:10.1053/eujp.2001.0324. PMID 11888243. S2CID 22742865.
- Pappagallo M (October 2003). "Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine". Clinical Therapeutics. 25 (10): 2506–2538. CiteSeerX 10.1.1.451.9407. doi:10.1016/S0149-2918(03)80314-4. PMID 14667954.
- Bou Ghannam A, Pelak VS (March 2017). "Visual Snow: a Potential Cortical Hyperexcitability Syndrome". Current Treatment Options in Neurology. 19 (3): 9. doi:10.1007/s11940-017-0448-3. PMID 28349350. S2CID 4829787.
- Wiffen PJ, Derry S, Moore RA (December 2013). "Lamotrigine for chronic neuropathic pain and fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2013 (12): CD006044. doi:10.1002/14651858.CD006044.pub4. PMC 6485508. PMID 24297457.
- Hussain A, Dar MA, Wani RA, Shah MS, Jan MM, Malik YA, et al. (2015). "Role of lamotrigine augmentation in treatment-resistant obsessive compulsive disorder: a retrospective case review from South Asia". Indian Journal of Psychological Medicine. 37 (2): 154–158. doi:10.4103/0253-7176.155613. PMC 4418246. PMID 25969599.
- Medford N (2005). "Understanding and treating depersonalisation disorder". Advances in Psychiatric Treatment. 11 (2): 92–100. doi:10.1192/apt.11.2.92.
- Hermle L, Simon M, Ruchsow M, Geppert M (October 2012). "Hallucinogen-persisting perception disorder". Therapeutic Advances in Psychopharmacology. 2 (5): 199–205. doi:10.1177/2045125312451270. PMC 3736944. PMID 23983976.
- Erfurth A, Walden J, Grunze H (October 1998). "Lamotrigine in the treatment of schizoaffective disorder" (PDF). Neuropsychobiology. 38 (3): 204–205. doi:10.1159/000026540. PMID 9778612. S2CID 46848204. Archived (PDF) from the original on 28 August 2021. Retrieved 9 September 2019.
- Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM (January 2010). "Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials". The British Journal of Psychiatry. 196 (1): 4–12. doi:10.1192/bjp.bp.108.062984. PMID 20044651.
- Williams T, Phillips NJ, Stein DJ, Ipser JC (March 2022). "Pharmacotherapy for post traumatic stress disorder (PTSD)". The Cochrane Database of Systematic Reviews. 2022 (3): CD002795. doi:10.1002/14651858.CD002795.pub3. PMC 8889888. PMID 35234292.
- "Lamotrigine (Lamictal) Treatment in adults with Attention Deficit Hyperactivity Disorder (ADHD), A pilot study" (PDF). Glaxo Smith Klein Clinical Study Register. Study No. LAM40120. Archived from the original (PDF) on 1 December 2017.
- Öncü B, Er O, Çolak B, Nutt DJ (March 2014). "Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series". Journal of Psychopharmacology. 28 (3): 282–283. doi:10.1177/0269881113493365. PMID 23784736. S2CID 8011752.
- "Lamictal (Lamotrigine): Uses, Dosage, Side Effects, Interactions, Warning". Archived from the original on 27 August 2016. Retrieved 26 August 2016.
- Serrani Azcurra DJ (June 2012). "Lamotrigine rechallenge after a skin rash. A combined study of open cases and a meta-analysis". Revista de Psiquiatria y Salud Mental. 6 (4): 144–149. doi:10.1016/j.rpsm.2012.04.002. PMID 23084805. Archived (PDF) from the original on 28 August 2021. Retrieved 10 December 2019.
- "Safety Alerts for Human Medical Products - Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction". www.fda.gov. Archived from the original on 25 July 2018. Retrieved 14 May 2018.
- Rissardo JP, Fornari Caprara AL (2021). "Lamotrigine-Associated Movement Disorder: A Literature Review". Neurology India. 69 (6): 1524–1538. doi:10.4103/0028-3886.333440. PMID 34979637. S2CID 245503954. Archived from the original on 2 February 2022. Retrieved 27 August 2022.
- Nicholson RJ, Kelly KP, Grant IS (February 1995). "Leucopenia associated with lamotrigine". BMJ. 310 (6978): 504. doi:10.1136/bmj.310.6978.504b. PMC 2548879. PMID 7888892.
- Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K, et al. (September 2008). "Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects" (PDF). British Journal of Clinical Pharmacology. 66 (3): 396–404. doi:10.1111/j.1365-2125.2008.03250.x. PMC 2526242. PMID 18662287. Archived from the original (PDF) on 9 August 2017.
- Motomura E, Tanii H, Usami A, Ohoyama K, Nakagawa M, Okada M (March 2012). "Lamotrigine-induced neuroleptic malignant syndrome under risperidone treatment: a case report". The Journal of Neuropsychiatry and Clinical Neurosciences. 24 (2): E38–E39. doi:10.1176/appi.neuropsych.11040093. PMID 22772697.
- Ishioka M, Yasui-Furukori N, Hashimoto K, Sugawara N (July–August 2013). "Neuroleptic malignant syndrome induced by lamotrigine". Clinical Neuropharmacology. 36 (4): 131–132. doi:10.1097/WNF.0b013e318294799a. PMID 23783003. S2CID 19508393.
- Reimers A, Helde G, Brodtkorb E (September 2005). "Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations". Epilepsia. 46 (9): 1414–1417. doi:10.1111/j.1528-1167.2005.10105.x. PMID 16146436. S2CID 7408965.
- "Product Information Lamotrigine Sandoz 25mg, 50mg, 100mg, 200mg, Dispersible/Chewable Tablets". TGA eBusiness Services. Sandoz Pty Ltd. 10 January 2017. Archived from the original on 23 August 2017. Retrieved 23 August 2017.
- Berwaerts K, Sienaert P, De Fruyt J (2009). "[Teratogenic effects of lamotrigine in women with bipolar disorder]". Tijdschrift voor Psychiatrie (in Dutch). 51 (10): 741–750. PMID 19821242.
- Prabhu LV, Nasar MA, Rai R, Madhyastha S, Singh G (October 2007). "Lamotrigine in pregnancy: safety profile and the risk of malformations". Singapore Medical Journal. 48 (10): 880–883. PMID 17909669.
- "Prescribing information, Lamictal" (PDF). GSK. February 2023. Archived (PDF) from the original on 23 March 2023. Retrieved 25 April 2023.
- Dalili H, Nayeri F, Shariat M, Asgarzadeh L (July 2015). "Lamotrigine effects on breastfed infants". Acta Medica Iranica. 53 (7): 393–394. PMID 26520624.
- Hale TW (2008). Medications and Mothers' Milk (13th ed.). Hale Publishing. p. 532. ISBN 978-0-9815257-2-3.
- "Lamictal, Warnings & Precautions". RxList Inc. Archived from the original on 29 June 2021. Retrieved 2 November 2020.
- Foldvary N, Perry M, Lee J, Dinner D, Morris HH (December 2001). "The effects of lamotrigine on sleep in patients with epilepsy". Epilepsia. 42 (12): 1569–1573. doi:10.1046/j.1528-1157.2001.46100.x. PMID 11879368. S2CID 12218913.
- Bonanni E, Galli R, Gori S, Pasquali L, Maestri M, Iudice A, Murri L (June 2001). "Neurophysiological evaluation of vigilance in epileptic patients on monotherapy with lamotrigine". Clinical Neurophysiology. 112 (6): 1018–1022. doi:10.1016/S1388-2457(01)00537-5. hdl:11568/186375. PMID 11377260. S2CID 6983433.
- Placidi F, Marciani MG, Diomedi M, Scalise A, Pauri F, Giacomini P, Gigli GL (August 2000). "Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy". Acta Neurologica Scandinavica. 102 (2): 81–86. doi:10.1034/j.1600-0404.2000.102002081.x. PMID 10949523. S2CID 24323287.
- Sadler M (March 1999). "Lamotrigine associated with insomnia". Epilepsia. 40 (3): 322–325. doi:10.1111/j.1528-1157.1999.tb00712.x. PMID 10080513. S2CID 43902298.
- "Review: could Lamictal cause Myoclonic jerks?". eHealthMe. 2016. Archived from the original on 29 January 2016.
- Rogawski M (2002). "Chapter 1: Principles of antiepileptic drug action". In Levy RH, Mattson RH, Meldrum BS, Perucca E (eds.). Antiepileptic Drugs, Fifth Edition. Lippincott Williams & Wilkins. pp. 3–22. ISBN 9780781723213.
- Rogawski MA, Löscher W (July 2004). "The neurobiology of antiepileptic drugs". Nature Reviews. Neuroscience. 5 (7): 553–564. doi:10.1038/nrn1430. PMID 15208697. S2CID 2201038. Archived from the original on 16 December 2020. Retrieved 31 August 2020.
- Lees G, Leach MJ (May 1993). "Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex". Brain Research. 612 (1–2): 190–199. doi:10.1016/0006-8993(93)91660-K. PMID 7687190. S2CID 20535234.
- "Prescribing Information for LAMICTAL (lamotrigine)" (PDF). FDA. Archived (PDF) from the original on 12 January 2020. Retrieved 12 January 2020.
- Thomas SP, Nandhra HS, Jayaraman A (April 2010). "Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD)". Journal of Mental Health. 19 (2): 168–175. doi:10.3109/09638230903469269. PMID 20433324. S2CID 39871557.
- Ketter TA, Manji HK, Post RM (October 2003). "Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders". Journal of Clinical Psychopharmacology. 23 (5): 484–495. doi:10.1097/01.jcp.0000088915.02635.e8. PMID 14520126. S2CID 35902870.
- Braga MF, Aroniadou-Anderjaska V, Post RM, Li H (March 2002). "Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders". Neuropharmacology. 42 (4): 522–529. doi:10.1016/s0028-3908(01)00198-8. PMID 11955522. S2CID 26174058.
- Shiah IS, Yatham LN, Gau YC, Baker GB (May 2003). "Effect of lamotrigine on plasma GABA levels in healthy humans". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27 (3): 419–423. doi:10.1016/S0278-5846(03)00028-9. PMID 12691776. S2CID 19209195.
- Southam E, Kirkby D, Higgins GA, Hagan RM (September 1998). "Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats". European Journal of Pharmacology. 358 (1): 19–24. doi:10.1016/s0014-2999(98)00580-9. PMID 9809864.
- Ramsay RE, Pellock JM, Garnett WR, Sanchez RM, Valakas AM, Wargin WA, et al. (1991). "Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy". Epilepsy Research. 10 (2–3): 191–200. doi:10.1016/0920-1211(91)90012-5. PMID 1817959. S2CID 34525226.
- Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW (November 1987). "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans". Clinical Pharmacology and Therapeutics. 42 (5): 535–541. doi:10.1038/clpt.1987.193. PMID 3677542. S2CID 19710948.
- Werz MA (October 2008). "Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release". Therapeutics and Clinical Risk Management. 4 (5): 1035–1046. doi:10.2147/TCRM.S3343. PMC 2621406. PMID 19209284.
- Goa KL, Ross SR, Chrisp P (July 1993). "Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy". Drugs. 46 (1): 152–176. doi:10.2165/00003495-199346010-00009. PMID 7691504.
- Anderson GD (May 1998). "A mechanistic approach to antiepileptic drug interactions". The Annals of Pharmacotherapy. 32 (5): 554–563. doi:10.1345/aph.17332. PMID 9606477. S2CID 43441971.
- CA patent 1112643, Baxter MG, Sawyer DA, Miller AA, Elphick AR, "3,5-diamino-6-phenyl-1,2,4-triazines", published 1981-11-17, assigned to Wellcome Foundation Ltd
- Leitch DC, John MP, Slavin PA, Searle AD (2017). "An Evaluation of Multiple Catalytic Systems for the Cyanation of 2,3-Dichlorobenzoyl Chloride: Application to the Synthesis of Lamotrigine". Organic Process Research & Development. 21 (11): 1815–1821. doi:10.1021/acs.oprd.7b00262.
- Kitson PJ, Marie G, Francoia JP, Zalesskiy SS, Sigerson RC, Mathieson JS, Cronin L (January 2018). "Digitization of multistep organic synthesis in reactionware for on-demand pharmaceuticals" (PDF). Science. 359 (6373): 314–319. Bibcode:2018Sci...359..314K. doi:10.1126/science.aao3466. PMID 29348235. S2CID 206663094. Archived (PDF) from the original on 21 April 2023. Retrieved 21 April 2023.
- Engel J (2013). Seizures and Epilepsy. OUP USA. p. 567. ISBN 9780195328547. Archived from the original on 2 August 2021. Retrieved 31 August 2020.
- "EFFICACY SUPPLEMENTS APPROVED IN CALENDAR YEAR 2003". FDA/Center for Drug Evaluation and Research. 19 March 2004. Archived from the original on 21 February 2008. Retrieved 9 April 2008.
- "Treatment for epilepsy: generic lamotrigine". Department of Health (UK). 2 March 2005. Archived from the original on 24 May 2012. Retrieved 9 April 2008.
- "Lamictal Prescribing Information" (PDF). GlaxoSmithKline. 2021. Archived (PDF) from the original on 26 October 2022. Retrieved 25 October 2022.
- "Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease". FDA Drug Safety Podcast. 20 January 2022. Archived from the original on 26 October 2022. Retrieved 25 October 2022.
- Auerbach DS, Muniz CF (April 2022). "Cardiac Safety of Lamotrigine: Still Awaiting a Verdict". Neurology. 98 (17): 697–698. doi:10.1212/WNL.0000000000200189. PMID 35260441. S2CID 247316861.
- Harmer AR, Valentin JP, Pollard CE (September 2011). "On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex". British Journal of Pharmacology. 164 (2): 260–273. doi:10.1111/j.1476-5381.2011.01415.x. PMC 3174407. PMID 21480866.
- Bunschoten JW, Husein N, Devinsky O, French JA, Sander JW, Thijs RD, Keezer MR (April 2022). "Sudden Death and Cardiac Arrythmia With Lamotrigine: A Rapid Systematic Review". Neurology. 98 (17): e1748–e1760. doi:10.1212/WNL.0000000000200164. PMID 35260442. S2CID 247317933.
- Aboukaoud M, Wilf-Yarkoni A, Maor E (September 2023). "Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis". Epilepsia. 64 (9): 2322–2329. doi:10.1111/epi.17696. PMID 37350356. S2CID 259231884.
- Treadwell JR, Wu M, Tsou AY (October 2022). Management of Infantile Epilepsies [Internet] (Report). Rockville (MD): Agency for Healthcare Research and Quality (US). doi:10.23970/ahrqepccer252. PMID 36383706. S2CID 254357105. Report No.: 22(23)-EHC004 2021-SR-01. Retrieved 12 July 2023.